Home » Topics » Regulatory » EMA

EMA
RSS

EMA completes arbitration procedure regarding Levact and associated names

March 23, 2010

EMA recommends harmonization of prescribing information for Atacand and associated names

March 23, 2010

OSI receives positive opinion on Tarceva for NSCLC from European health authorities

March 22, 2010

Pharming submits response to CHMP for Rhucin MAA for hereditary angioedema

March 19, 2010

Cangene receives European approval for ImmunoGam hepatitis B product

March 18, 2010

Novartis receives E.U. approval for meningococcal Menveo vaccine

March 18, 2010

FDA and EMA grant orphan drug status to ImmunoGen's IMGN-901 in MCC

March 9, 2010

EMA accepts voclosporin for regulatory review

March 3, 2010

Ariad's AP-24534 receives orphan drug status for CML

March 2, 2010

COMP grants perifosine positive opinion as orphan medicinal product in MM

March 2, 2010

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
At AACR: Epigenetic fingerprints in metastases track tumor origin
BioWorld
When a tumor migrates and colonizes another tissue or organ, it can be identified as a metastasis, but its origin is not always clear. Now, a study based on...
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...